Acne Vulgaris Market to Register Sustainable Growth by 2034, Examines DelveInsight | Key Companies - Dermata Therapeutics, AstraZeneca, Novartis Pharmaceuticals, UCB Pharma, Incyte Corpora...
Dermata Therapeutics, Inc. (DRMA)
Company Research
Source: Yahoo! Finance
LAS VEGAS May 27, 2024 /PRNewswire/ -- DelveInsight's Acne Vulgaris Market Insights report includes a comprehensive understanding of current treatment practices, acne vulgaris emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [ the United States , the EU4 ( Germany France Italy , and Spain ) and the United Kingdom , and Japan ]. Key Takeaways from the Acne Vulgaris Market Report According to DelveInsight's analysis, the market size for acne vulgaris is expected to grow significantly by 2034. As per DelveInsight's estimates, acne vulgaris affects of Americans at some time during their lives. This rate is expected to increase in the forecasted period. About of people worldwide have acne vulgaris, with teens having the highest prevalence of the condition. In all ethnic groupings, it affects more than of men and of women. Leading acne vulgaris companies such as Dermata Therapeutics, AstraZeneca, No
Show less
Read more
Impact Snapshot
Event Time:
DRMA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DRMA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DRMA alerts
High impacting Dermata Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
DRMA
News
- Moderate to Severe Acne Pipeline Landscape Analysis, 2024, Featuring Emerging Therapies ASC40 (Ascletis Pharma), BTX 1503 (Botanix Pharmaceuticals), and More [Yahoo! Finance]Yahoo! Finance
- Dermata Therapeutics Announces Exercise of Warrants for $2.66 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules [Yahoo! Finance]Yahoo! Finance
- Dermata Therapeutics Announces Exercise of Warrants for $2.66 Million in Gross Proceeds Priced At-the-Market Under Nasdaq RulesAccesswire
- Dermata to Present at the Emerging Growth Conference on April 3, 2024 [Yahoo! Finance]Yahoo! Finance
- Dermata to Present at the Emerging Growth Conference on April 3, 2024Accesswire
DRMA
Sec Filings
- 6/7/24 - Form 8-K
- 6/7/24 - Form 424B5
- 6/5/24 - Form 8-K
- DRMA's page on the SEC website